# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances
0, Journal, 0, 12, "Diabet Med .", "", "<http://ctro/data#Publication_29847> <http://ctro/data#hasJournal> \"Diabet Med .\"."
1, PublicationYear, 13, 17, "2011", "", "<http://ctro/data#Publication_29847> <http://ctro/data#hasPublicationYear> \"2011\"."
9, Title, 103, 274, "Efficacy and safety of linagliptin in persons with type 2 diabetes inadequately controlled by a combination of metformin and sulphonylurea : a 24 - week randomized study .", "", "<http://ctro/data#Publication_29847> <http://ctro/data#hasTitle> \"Efficacy and safety of linagliptin in persons with type 2 diabetes inadequately controlled by a combination of metformin and sulphonylurea : a 24 - week randomized study .\"."
2, Linagliptin, 126, 137, "linagliptin", "", 
8, Precondition, 141, 241, "persons with type 2 diabetes inadequately controlled by a combination of metformin and sulphonylurea", "", 
3, Type2Diabetes, 154, 169, "type 2 diabetes", "", "<http://ctro/data#ClinicalTrial_29854> <http://ctro/data#analysesHealthCondition> <http://ctro/data#Type2Diabetes>."
4, Metformin, 214, 223, "metformin", "", 
5, Sulfonylureas, 228, 241, "sulphonylurea", "", 
6, Duration, 246, 255, "24 - week", "", "<http://ctro/data#ClinicalTrial_29854> <http://ctro/data#hasCTduration> \"24 - week\"."
7, Randomized, 256, 266, "randomized", "", "<http://ctro/data#ClinicalTrial_29854> <http://ctro/data#hasCTDesign> <http://ctro/data#Randomized>."
10, Author, 275, 283, "Owens DR", "", "<http://ctro/data#Publication_29847> <http://ctro/data#hasAuthor> \"Owens DR\"."
11, Author, 292, 301, "Swallow R", "", "<http://ctro/data#Publication_29847> <http://ctro/data#hasAuthor> \"Swallow R\"."
12, Author, 304, 311, "Dugi KA", "", "<http://ctro/data#Publication_29847> <http://ctro/data#hasAuthor> \"Dugi KA\"."
13, Author, 314, 323, "Woerle HJ", "", "<http://ctro/data#Publication_29847> <http://ctro/data#hasAuthor> \"Woerle HJ\"."
14, UK, 395, 397, "UK", "", "<http://ctro/data#Population_29870> <http://ctro/data#hasCountry> <http://ctro/data#UK>."
23, ObjectiveDescription, 531, 619, "To examine the efficacy and safety of the dipeptidyl peptidase - 4 inhibitor linagliptin", "", 
15, Linagliptin, 608, 619, "linagliptin", "", 
24, ObjectiveDescription, 620, 794, "in persons with Type 2 diabetes mellitus inadequately controlled [ HbA ( 1c ) 53 - 86 mmol / mol ( 7 . 0 - 10 . 0 % ) ] by metformin and sulphonylurea combination treatment .", "", "<http://ctro/data#ClinicalTrial_29854> <http://ctro/data#hasObjectiveDescription> \"in persons with Type 2 diabetes mellitus inadequately controlled [ HbA ( 1c ) 53 - 86 mmol / mol ( 7 . 0 - 10 . 0 % ) ] by metformin and sulphonylurea combination treatment .\"."
22, Precondition, 623, 792, "persons with Type 2 diabetes mellitus inadequately controlled [ HbA ( 1c ) 53 - 86 mmol / mol ( 7 . 0 - 10 . 0 % ) ] by metformin and sulphonylurea combination treatment", "", "<http://ctro/data#Population_29870> <http://ctro/data#hasPrecondition> \"persons with Type 2 diabetes mellitus inadequately controlled [ HbA ( 1c ) 53 - 86 mmol / mol ( 7 . 0 - 10 . 0 % ) ] by metformin and sulphonylurea combination treatment\"."
16, Type2Diabetes, 636, 660, "Type 2 diabetes mellitus", "", 
17, HbA1c, 687, 697, "HbA ( 1c )", "", 
79730, Millimoles_per_mole, 706, 710, "mmol", "", 
18, Percentage, 734, 735, "%", "", 
20, Metformin, 743, 752, "metformin", "", 
21, Sulfonylureas, 757, 770, "sulphonylurea", "", 
25, Multicenter, 807, 821, "multi - centre", "", "<http://ctro/data#ClinicalTrial_29854> <http://ctro/data#hasCTDesign> <http://ctro/data#Multicenter>."
26, Duration, 824, 833, "24 - week", "", 
27, Randomized, 836, 846, "randomized", "", 
28, DoubleBlind, 849, 863, "double - blind", "", "<http://ctro/data#ClinicalTrial_29854> <http://ctro/data#hasCTDesign> <http://ctro/data#DoubleBlind>."
29, Parallel, 866, 882, "parallel - group", "", "<http://ctro/data#ClinicalTrial_29854> <http://ctro/data#hasCTDesign> <http://ctro/data#Parallel>."
30, NumberPatientsCT, 892, 896, "1058", "", "<http://ctro/data#ClinicalTrial_29854> <http://ctro/data#hasNumberPatientsCT> \"1058\"."
31, Linagliptin, 916, 927, "linagliptin", "", "<http://ctro/data#Medication_29920> <http://ctro/data#hasDrug> <http://ctro/data#Linagliptin>."
32, DoseValue, 930, 931, "5", "", "<http://ctro/data#Medication_29920> <http://ctro/data#hasDoseValue> \"5\"."
33, mg, 932, 934, "mg", "", "<http://ctro/data#Medication_29920> <http://ctro/data#hasDoseUnit> <http://ctro/data#mg>."
34, Frequency, 935, 945, "once daily", "", "<http://ctro/data#Intervention_29896> <http://ctro/data#hasFrequency> \"once daily\"."
35, Placebo, 952, 959, "placebo", "", "<http://ctro/data#Medication_29927> <http://ctro/data#hasDrug> <http://ctro/data#Placebo>."
36, Metformin, 974, 983, "metformin", "", 
37, Sulfonylureas, 989, 1002, "sulphonylurea", "", 
38, HbA1c, 1044, 1054, "HbA ( 1c )", "", 
139, TimePoint, 1061, 1069, "24 weeks", "", 
99, TimePoint, 1085, 1092, "week 24", "", "<http://ctro/data#Outcome_29967> <http://ctro/data#hasTimePoint> \"week 24\". <http://ctro/data#Outcome_91794> <http://ctro/data#hasTimePoint> \"week 24\"."
40, Linagliptin, 1099, 1110, "linagliptin", "", 
41, Placebo, 1111, 1118, "placebo", "", 
42, HbA1c, 1131, 1141, "HbA ( 1c )", "", "<http://ctro/data#Endpoint_29962> <http://ctro/data#hasEndoPointDescription> <http://ctro/data#HbA1c>."
144, Mean, 1151, 1155, "mean", "", "<http://ctro/data#Mean_29964> <http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://ctro/data#Mean>. <http://ctro/data#Endpoint_29962> <http://ctro/data#hasAggregationMethod> <http://ctro/data#Mean_29964>."
145, TimePoint, 1168, 1176, "baseline", "", 
106305, DiffGroupAbsValue, 1181, 1184, "- 7", "", 
79735, Millimoles_per_mole, 1185, 1195, "mmol / mol", "", "<http://ctro/data#Endpoint_29962> <http://ctro/data#hasBaselineUnit> <http://ctro/data#Millimoles_per_mole>."
106307, DiffGroupAbsValue, 1198, 1206, "- 0 . 62", "", "<http://ctro/data#DiffBetweenGroups_91821> <http://ctro/data#hasDiffGroupAbsValue> \"- 0 . 62\"."
46, Percentage, 1207, 1208, "%", "", 
106309, ConfIntervalDiff, 1213, 1267, "95 % CI - 8 to - 6 mmol / mol ( - 0 . 73 to - 0 . 50 %", "", "<http://ctro/data#DiffBetweenGroups_91821> <http://ctro/data#hasConfIntervalDiff> \"95 % CI - 8 to - 6 mmol / mol ( - 0 . 73 to - 0 . 50 %\"."
79741, Millimoles_per_mole, 1232, 1242, "mmol / mol", "", 
49, Percentage, 1266, 1267, "%", "", 
106308, PvalueDiff, 1272, 1284, "P < 0 . 0001", "", "<http://ctro/data#DiffBetweenGroups_91821> <http://ctro/data#hasPvalueDiff> \"P < 0 . 0001\"."
166, SubGroupDescription, 1294, 1361, "participants with baseline HbA ( 1c ) ≥ 53 mmol / mol ( ≥ 7 . 0 % )", "", "<http://ctro/data#Outcome_29994> <http://ctro/data#hasSubGroupDescription> \"participants with baseline HbA ( 1c ) ≥ 53 mmol / mol ( ≥ 7 . 0 % )\". <http://ctro/data#Outcome_30026> <http://ctro/data#hasSubGroupDescription> \"participants with baseline HbA ( 1c ) ≥ 53 mmol / mol ( ≥ 7 . 0 % )\"."
156, HbA1c, 1321, 1331, "HbA ( 1c )", "", 
79745, Millimoles_per_mole, 1337, 1347, "mmol / mol", "", 
158, Percentage, 1358, 1359, "%", "", 
59540, HbA1c_target, 1374, 1414, "HbA ( 1c ) < 53 mmol / mol ( < 7 . 0 % )", "", "<http://ctro/data#Endpoint_30021> <http://ctro/data#hasEndoPointDescription> <http://ctro/data#HbA1c_target>."
79747, Millimoles_per_mole, 1390, 1400, "mmol / mol", "", 
160, Percentage, 1411, 1412, "%", "", 
50, Linagliptin, 1420, 1431, "linagliptin", "", 
51, Placebo, 1446, 1453, "placebo", "", 
54, PercentageAffected, 1456, 1462, "29 . 2", "", 
55, PercentageAffected, 1470, 1475, "8 . 1", "", "<http://ctro/data#Outcome_30026> <http://ctro/data#hasPercentageAffected> \"8 . 1\"."
56, PvalueDiff, 1480, 1492, "P < 0 . 0001", "", "<http://ctro/data#DiffBetweenGroups_30053> <http://ctro/data#hasPvalueDiff> \"P < 0 . 0001\"."
58, FastingPlasmaGlucose, 1497, 1519, "Fasting plasma glucose", "", "<http://ctro/data#Endpoint_30062> <http://ctro/data#hasEndoPointDescription> <http://ctro/data#FastingPlasmaGlucose>."
59, Linagliptin, 1537, 1548, "linagliptin", "", 
60, Placebo, 1561, 1568, "placebo", "", 
106310, DiffGroupAbsValue, 1571, 1578, "- 0 . 7", "", "<http://ctro/data#DiffBetweenGroups_91858> <http://ctro/data#hasDiffGroupAbsValue> \"- 0 . 7\"."
62, Millimoles_per_litre, 1579, 1587, "mmol / l", "", "<http://ctro/data#Endpoint_30062> <http://ctro/data#hasBaselineUnit> <http://ctro/data#Millimoles_per_litre>."
106311, ConfIntervalDiff, 1590, 1616, "95 % CI - 1 . 0 to - 0 . 4", "", "<http://ctro/data#DiffBetweenGroups_91858> <http://ctro/data#hasConfIntervalDiff> \"95 % CI - 1 . 0 to - 0 . 4\"."
106312, PvalueDiff, 1619, 1631, "P < 0 . 0001", "", "<http://ctro/data#DiffBetweenGroups_91858> <http://ctro/data#hasPvalueDiff> \"P < 0 . 0001\"."
106313, ObservedResult, 1636, 1727, "Improvements in homeostasis model assessment of β- cell function were seen with linagliptin", "", "<http://ctro/data#Outcome_30099> <http://ctro/data#hasObservedResult> \"Improvements in homeostasis model assessment of β- cell function were seen with linagliptin\"."
65, EndPointDescription, 1652, 1700, "homeostasis model assessment of β- cell function", "", "<http://ctro/data#EndPointDescription_30095> <http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://ctro/data#EndPointDescription>. <http://ctro/data#Endpoint_30094> <http://ctro/data#hasEndoPointDescription> <http://ctro/data#EndPointDescription_30095>."
66, Linagliptin, 1716, 1727, "linagliptin", "", 
180, PValueChangeValue, 1730, 1741, "P < 0 . 001", "", "<http://ctro/data#Outcome_30099> <http://ctro/data#hasPValueChangeValue> \"P < 0 . 001\"."
181, EndPointDescription, 1788, 1808, "severe adverse event", "", "<http://ctro/data#EndPointDescription_30127> <http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://ctro/data#EndPointDescription>. <http://ctro/data#Endpoint_30126> <http://ctro/data#hasEndoPointDescription> <http://ctro/data#EndPointDescription_30127>."
71, Linagliptin, 1834, 1845, "linagliptin", "", 
69, PercentageAffected, 1846, 1851, "2 . 4", "", "<http://ctro/data#Outcome_30131> <http://ctro/data#hasPercentageAffected> \"2 . 4\"."
72, Placebo, 1856, 1863, "placebo", "", 
70, PercentageAffected, 1864, 1869, "1 . 5", "", "<http://ctro/data#Outcome_30158> <http://ctro/data#hasPercentageAffected> \"1 . 5\"."
73, SymptomaticHypoglycemia, 1876, 1901, "Symptomatic hypoglycaemia", "", "<http://ctro/data#Endpoint_30185> <http://ctro/data#hasEndoPointDescription> <http://ctro/data#SymptomaticHypoglycemia>."
74, PercentageAffected, 1914, 1920, "16 . 7", "", "<http://ctro/data#Outcome_30190> <http://ctro/data#hasPercentageAffected> \"16 . 7\"."
75, PercentageAffected, 1925, 1931, "10 . 3", "", "<http://ctro/data#Outcome_30217> <http://ctro/data#hasPercentageAffected> \"10 . 3\"."
76, Linagliptin, 1941, 1952, "linagliptin", "", 
77, Placebo, 1957, 1964, "placebo", "", 
78, Hypoglycemia, 1989, 2002, "Hypoglycaemia", "", 
82, ObservedResult, 2003, 2033, "was generally mild or moderate", "", 
79, SevereHypoglycemia, 2036, 2056, "severe hypoglycaemia", "", "<http://ctro/data#Endpoint_30244> <http://ctro/data#hasEndoPointDescription> <http://ctro/data#SevereHypoglycemia>."
80, PercentageAffected, 2073, 2078, "2 . 7", "", "<http://ctro/data#Outcome_30249> <http://ctro/data#hasPercentageAffected> \"2 . 7\"."
81, PercentageAffected, 2083, 2088, "4 . 8", "", "<http://ctro/data#Outcome_30276> <http://ctro/data#hasPercentageAffected> \"4 . 8\"."
199, SubGroupDescription, 2098, 2146, "participants experiencing hypoglycaemic episodes", "", "<http://ctro/data#Outcome_30249> <http://ctro/data#hasSubGroupDescription> \"participants experiencing hypoglycaemic episodes\". <http://ctro/data#Outcome_30276> <http://ctro/data#hasSubGroupDescription> \"participants experiencing hypoglycaemic episodes\"."
83, Hypoglycemia, 2124, 2146, "hypoglycaemic episodes", "", 
84, Linagliptin, 2154, 2165, "linagliptin", "", 
85, Placebo, 2170, 2177, "placebo", "", 
88, ObservedResult, 2202, 2242, "No significant weight changes were noted", "", 
202, BodyWeight, 2217, 2223, "weight", "", 
93, ConclusionComment, 2259, 2438, "In patients with Type 2 diabetes , adding linagliptin to metformin given in combination with a sulphonylurea significantly improved glycaemic control and this was well tolerated .", "", "<http://ctro/data#ClinicalTrial_29854> <http://ctro/data#hasConclusionComment> \"In patients with Type 2 diabetes , adding linagliptin to metformin given in combination with a sulphonylurea significantly improved glycaemic control and this was well tolerated .\"."
89, Type2Diabetes, 2276, 2291, "Type 2 diabetes", "", 
90, Linagliptin, 2301, 2312, "linagliptin", "", 
91, Metformin, 2316, 2325, "metformin", "", 
92, Sulfonylureas, 2354, 2367, "sulphonylurea", "", 
94, Linagliptin, 2439, 2450, "Linagliptin", "", 
97, ConclusionComment, 2439, 2615, "Linagliptin could provide a valuable treatment option for individuals with inadequate glycaemic control despite ongoing combination therapy with metformin and a sulphonylurea .", "", "<http://ctro/data#ClinicalTrial_29854> <http://ctro/data#hasConclusionComment> \"Linagliptin could provide a valuable treatment option for individuals with inadequate glycaemic control despite ongoing combination therapy with metformin and a sulphonylurea .\"."
95, Metformin, 2584, 2593, "metformin", "", 
96, Sulfonylureas, 2600, 2613, "sulphonylurea", "", 
98, PMID, 2736, 2744, "21781152", "", "<http://ctro/data#Publication_29847> <http://ctro/data#hasPMID> \"21781152\"."
